Visual analogue scale - a tool for assessing the control of allergic rhinitis

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Allergic rhinitis (AR) is the most common form of rhinitis and the most common allergic disease in children and adults. Numerous clinical studies and daily practice indicate a pronounced negative effect of symptoms of AR on patients’ quality of life, their usual daily activity, cognitive functions, mood and sleep. The type and severity of individual symptoms can vary from patient to patient, and therapy should be directed to the overall control of the symptoms of AR. It is important to obtain reliable and comparable information regarding the severity of AR symptoms before, during and after the treatment, which can be assessed using a simple and accessible tool - a visual analogue scale (VAS). VAS validated for patients with AR allows to define a controlled, partially controlled and uncontrolled AR. The article proposes an algorithm for the treatment of AR, depending on the severity of the symptoms, assessed using VAS.

Restricted Access

N M Nenasheva

FGBOU DPO Russian Medical Academy of Continuing Professional Education


E P Terekhova

FGBOU DPO Russian Medical Academy of Continuing Professional Education

O S Bodnya

FGBOU DPO Russian Medical Academy of Continuing Professional Education

O V Sebekina

FGBOU DPO Russian Medical Academy of Continuing Professional Education

  1. Hellings PW, Borelli D, Pjetikainen S, Agache I, Akdis C, Bachert C et al. European Summit on the Prevention and Self-Management of Chronic Respiratory Diseases: report of the European Union Parliament Summit (29 March 2017). Clin Transl Allergy. 2017;7:49. doi: 10.1186/s13601-017-0186-3.
  2. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J. 2004;24:758-764.
  3. Asher MI, Montefort S, Bjorksten B et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three re- 19. peat multicountry cross-sectional surveys. Lancet. 2006;368:733-743.
  4. Chuchalin AG, Khaltaev N, Antonov NS, Galkin DV, Manakov LG, Antonini P et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. International Journal of COPD. 2014;9:963-974.
  5. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy. 2008;63:8-160.
  6. Rondón C, Campo P, Togias A, Fokkens WJ, Durham SR, Powe DG, Mullol J, Blanca M. Local allergic rhinitis: concept, pathophysiology, and management. J Allergy Clin Immunol. 2012;129(6):1460-1467.
  7. Carney AS, Powe DG, Huskisson RS, Jones NS. Atypical nasal challenges in patients with idiopathic rhinitis: more evidence for the existence of allergy in the absence of atopy? Clin Exp Allergy. 2002;32:1436-1440.
  8. Bousquet PJ, Demoly P, Devillier P, Mesbah K, Bousquet J. Impact of allergic rhinitis symptoms on quality of life in primary care. Int Arch Allergy Immunol. 2013;160:393-400. doi: 10.1159/000342991.
  9. Meltzer EO, Gross GN, Katial R, Storms WW Allergic rhinitis substantially impacts patient quality of life: findings from the Nasal Allergy Survey Assessing Limitations. J Fam Pract. 2012;61:5-10.
  10. Valovirta E, Myrseth SE, Palkonen S. The voice ofthe patients: allergic rhinitis is not a trivial disease. Curr Opin Allergy Clin Immunol. 2008;8:1-9. doi: 10.1097/ACI.0b013e3282f3f42f.
  11. Braido F, Baiardini I, Scichilone N, Musarra A, Menoni S, Ridolo E et al. Illness perception, mood and coping strategies in allergic rhinitis: are there differences among ARIA classes of severity? Rhinology. 2014;52:66-71.
  12. Small M, Piercy J, Demoly P, Marsden H. Burden of illness and quality of life in patients being treated for seasonal allergic rhinitis: a cohort survey. Clin Transl Allergy. 2013;3:33. doi: 10.1186/2045-7022-3-33.
  13. Walker S, Khan-Wasti S, Fletcher M, Cullinan P, Harris J, Sheikh A. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol. 2007;120:381-387. doi: 10.1016/j.jaci.2007.03.034.
  14. Clatworthy J, Price D, Ryan D, Haughney J, Horne R. The value of self-report assessment of adherence, rhinitis and smoking in relation to asthma control. Prim Care Respir J. 2009;18:300-305. doi: 10.4104/pcrj.2009.00037.
  15. Mullol J, Bartra J, Del CA, Izquierdo I, Munoz-Cano R, Valero A. Specialist-based treatment reduces the severity of allergic rhinitis. Clin Exp Allergy. 2013;43:723-729. doi: 10.1111/cea.12081.
  16. Bousquet J, Annesi-Maesano I, Carat F, Leger D, Rugina M, Pribil C et al. Characteristics of intermittent and persistent allergic rhinitis: DREAMS study group. Clin Exp Allergy. 2005;35:728-732. doi: 10.1111/j.1365-2222.2005.02274.x.
  17. Hellings PW, Dobbels F, Denhaerynck K, Piessens M, Ceuppens JL, De GS. Explorative study on patient’s perceived knowledge level, expectations, preferences and fear of side effects for treatment for allergic rhinitis. Clin Transl Allergy. 2012;2:9. doi: 10.1186/2045-7022-2-9.
  18. Ciprandi G, Incorvaia C, Scurati S, Puccinelli P, Soffia S, Frati F et al. Patient-related factors in rhinitis and asthma: the satisfaction with allergy treatment survey. Curr Med Res Opin. 2011;27:1005-1011. doi: 10.1185/03007995.2011.559580.
  19. Valovirta E, Ryan D. Patient adherence to allergic rhinitis treatment: results from patient surveys. Medscape J Med. 2008;10:247.
  20. Roberts G, Xatzipsalti M, Borrego LM, Custovic A, Halken S, Hellings PW, Papadopoulos NG, Rotiroti G, Scadding G, Timmermans F, Valovirta E. Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. Allergy. 2013;68:1102-1116.
  21. Papadopoulos NG, Bernstein JA, Demoly P, Dykewicz M, Fokkens W, Hellings PW, Peters AT, Rondon C, Togias A, Cox LS. Phenotypes and endotypes of rhinitis and their impact on management: a PRACTALL report. Allergy. 2015;70:474-494.
  22. Bousquet PJ1, Combescure C, Neukirch F, Klossek JM, Méchin H, Daures JP, Bousquet J. Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines. Allergy. 2007;62:367-372.
  23. Murphy DF, McDonald A, Power C, Unwin A, MacSullivan R. Measurement of pain: a comparison of the visual analogue with a nonvisual analogue scale. Clin J Pain. 1987;3:197-199. doi: 10.1097/00002508-198712000-00003.
  24. Bousquet PJ, Bachert C, Canonica GW, Casale TB, Mullol J, Klossek JM, Zuberbier T, Bousquet J. Uncontrolled allergic rhinitis during treatment and its impact on quality of life: a cluster randomized trial. J Allergy Clin Immunol. 2010;126:666-668.
  25. Demoly P, Bousquet PJ, Mesbah K, Bousquet J, Devillier P. Visual analogue scale in patients treated for allergic rhinitis: an observational prospective study in primary care: asthma and rhinitis. Clin Exp Allergy. 2013;43:881-888. DOI: 10.1111/ cea.12121.
  26. Bousquet J, Bachert C, Canonica GW, Mullol J, van Cauwenberge P, Bindslev Jensen C et al. Efficacy of desloratadine in intermittent allergic rhinitis: a GA2LEN study. Allergy. 2009;64:1516-1523. doi: 10.1111/j.1398-9995.2009.02115.x.
  27. Bousquet J, Bachert C, Canonica GW, Mullol J, van Cauwenberge P, ACCEPT-2 study group et al. Efficacy of desloratadine in persistent allergic rhinitis - a GA2LEN study. Int Arch Allergy Immunol. 2010;153:395-402. doi: 10.1159/000316351.
  28. Morais-Almeida M, Santos N, Pereira AM, Branco-Fer-reira M, Nunes C, Bousquet J, Fonseca JA. Prevalence and classification of rhinitis in preschool children in Portugal: a nationwide study. Allergy. 2013;68:1278-1288. DOI: 10.1111/ all.12221.
  29. Morais-Almeida M, Pite H, Pereira AM, Todo-Bom A, Nunes C, Bousquet J et al. Prevalence and classification of rhinitis in the elderly: a nationwide survey in Portugal. Allergy. 2013;68:1150-1157. doi: 10.1111/all.12221.
  30. Bourret R, Bousquet J. An integrated approach to telemonitoring noncommunicable diseases: best practice from the European innovation partnership on active and healthy ageing. World Hosp Health Serv. 2013;49:25-28.
  31. Bousquet J, Schunemann HJ, Fonseca J, Samolinski B, Bachert C, Canonica GW et al. MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. Allergy. 2015;70:1372-1392.
  32. Bousquet J, Barbara C, Bateman E, Bel E, Bewick M, Chavannes NH, Cruz AA, Haahtela T, Hellings PW, Khaltaev N, Lodrup Carlsen K, Muraro A, Cordeiro CR, Rosado-Pinto J, Samolinski B, Strandberg T, Valiulis A, Yorgancioglu A, Zuberbier T AIRWAYS-ICPs working group. AIR-WAYS ICPs from concept to implementation. Eur Respir J. 2016;47:1028-1033.
  33. Muraro A, Lemanske RF Jr, Castells M, Torres MJ, Khan D, Simon HU, Bindslev-Jensen C, Burks W, Poulsen LK, Sampson HA, Worm M, Nadeau KC. Precision medicine in allergic disease-food allergy, drug allergy, and anaphylaxis - PRACTALL document of the European Academy of Allergy and Clinical Immunology. Allergy. 2017;72:1006-1021.
  34. Bousquet J, Schunemann H, Hellings P, Arnavielhe S, Bachert C, Bedbrook A et al. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. J Allergy Clin Immunol. 2016;138:367-374.
  35. Lipworth B, Newton J, Ram B, Small I, Schwarze J. An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel. NPJ Prim Care Respir Med. 2017;27:1-8.
  36. Brożek JL, Bousquet J., Agache I., Agarwal A., Bachert C., Bosnic-Anticevich S. et al. Allergic Rhinitis and its Impact on Asthma (ARIA) Guidelines - 2016 Revision. J. Allergy Clin Immunol. 2017;140(4):950-958. DOI: 10.1016/j. jaci.2017.03.050.
  37. Seidman MD, Gurgel RK, Lin S’Y. Schwartz SR, Baroody FM, Bonner JR et al. Clinical practice guideline: Allergic rhinitis. Otolaryngol Head Neck Surg. 2015;152:S1-43.
  38. Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J., Cox L., Khan DA et al. The diagnosis and management of rhinitis: an updated practice parameter. J. Allergy Clin Immunol. 2008;122:S1-84.
  39. Ненашева НМ, Ильина НИ, Федоскова ТГ Эффективность совместного применения интраназального кортикостероида и антигистаминного препарата у взрослых больных сезонным аллергическим ринитом на примере фиксированной комбинации мометазона фуроата и азеластина гидрохлорида в виде назального спрея (Результаты клинического исследования)». Российский Аллергологический Журнал. 2016;(2):54-62
  40. Ненашева НМ, Носуля ЕВ, Ким ИА, Рязанцев СВ, Овчинников АЮ, Бердникова Н.Г. Эффективность препарата Момат Рино Адванс (фиксированной комбинации мометазона фуроата и азеластина гидрохлорида в виде назального спрея) у взрослых больных круглогодичным аллергическим ринитом: результаты рандомизированного открытого многоцентрового клинического исследования. Consilium Medicum. Болезни органов дыхания (приложение). 2018;(1):38-47. doi: 10.26442/2619-0079.2018:38-47


Abstract - 38

PDF (Russian) - 1




  • There are currently no refbacks.

Copyright (c) 2018 Russian Allergological Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies